WithdrawnNot Applicable

Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

Stopped: Time and resource deficiency at the Stockholm CF Center.

Sweden0Started 2015-09-01

Plain-language summary

CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.

Who can participate

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CF patients not previously immunized against hepatitis A or B * Healthy volunteers not previously immunized against hepatitis A or B * Age over 1 year Exclusion Criteria: * Previously transplanted patients * Previous vaccination with hepatitis vaccine * Known allergy against components in Twinrix (TM)

What they're measuring

Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers

Timeframe: 6 months for vaccination

Trial details

NCT IDNCT02605538

SponsorKarolinska University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Cystic Fibrosis trials